A Pivotal Year Ahead for Annexon’s Clinical Ambitions

Annexon Inc US03589W1027

The coming year represents a critical inflection point for Annexon, Inc., as the biopharmaceutical company approaches key regulatory and clinical milestones for its pipeline of neuroinflammatory disease treatments. With a strategically important start to January now complete, investor focus shifts to the substantive progress expected across its core programs in 2026.

The company enters this decisive period with a stated financial foundation that provides operational runway through late 2027. This capital position is designed to allow management to execute on clinical objectives without the immediate pressure of seeking additional funding.

The market will receive an update on this financial standing shortly. Annexon is scheduled to release its fourth-quarter and full-year 2025 financial results on March 2. A conference call to discuss these results and provide a pipeline update is set for March 5. Subsequently, first-quarter 2026 figures are expected in mid-May.

Spotlight on Regulatory and Data Readouts

Central to the investment thesis for 2026 are two lead assets: tanruprubart and vonaprument.

• Tanruprubart (Guillain-Barré Syndrome): Regulatory momentum is building. Following last month's marketing authorization application submission to the European Medicines Agency (EMA), the company plans to file a corresponding application with U.S. regulators later this year.
• Vonaprument (Geographic Atrophy): All eyes are on the second half of the year for the release of topline data from the pivotal ARCHER II Phase 3 trial. An investor day planned for March aims to offer further strategic and commercial insights into this program.
• ANX1502: Additionally, initial proof-of-concept data for the oral C1s inhibitor ANX1502 are anticipated at some point during the year.

The convergence of these events—regulatory filings, pivotal data readouts, and financial updates—sets the stage for 2026 to be a potentially transformative period for Annexon, determining the near-term trajectory of its clinical portfolio.

@ boerse-global.de | US03589W1027 PIVOTAL